[A case of primary transitional cell carcinoma of the prostate responsive to combination chemotherapy with methotrexate, epirubicin and cisplatin]. 1998

K Abe, and Y Ohishi, and S Onodera, and H Kiyota, and K Asano
Department of Urology, Tokyo Jikei University School of Medicine.

A 72-year-old man with the chief complaint of macrohematuria was referred to our hospital in February 1996. On transrectal examination, the prostate was stony hard without nodules. Cystoscopic findings and biopsies did not confirm a transitional cell carcinoma or carcinoma in situ in the bladder. However transurethral and transrectal biopsy specimens of prostate showed transitional cell carcinoma invading the prostate stroma. Pelvic CT scan revealed a lymph node metastasis in the left iliac artery region. Under the diagnosis of primary transitional cell carcinoma of the prostate, radical cystoprostatectomy and lymph node dissection were performed after two courses of neoadjuvant systemic chemotherapy. Pathologically no viable transitional cell carcinoma could be found in any of the specimens. Thus neo-adjuvant systemic chemotherapy was very effective in this case.

UI MeSH Term Description Entries
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

K Abe, and Y Ohishi, and S Onodera, and H Kiyota, and K Asano
January 2001, Anticancer research,
K Abe, and Y Ohishi, and S Onodera, and H Kiyota, and K Asano
April 1987, The Journal of urology,
K Abe, and Y Ohishi, and S Onodera, and H Kiyota, and K Asano
January 1988, Archives of gynecology and obstetrics,
K Abe, and Y Ohishi, and S Onodera, and H Kiyota, and K Asano
November 1992, Hinyokika kiyo. Acta urologica Japonica,
K Abe, and Y Ohishi, and S Onodera, and H Kiyota, and K Asano
August 1992, Journal of chemotherapy (Florence, Italy),
K Abe, and Y Ohishi, and S Onodera, and H Kiyota, and K Asano
January 1996, The Journal of urology,
K Abe, and Y Ohishi, and S Onodera, and H Kiyota, and K Asano
March 1995, Hinyokika kiyo. Acta urologica Japonica,
Copied contents to your clipboard!